In the last two years, the sheer volume of scientific research focused on COVID-19 has been astounding: thousands of clinical studies, dozens of vaccines and new compounds, and hundreds of approved drugs tested for efficacy. More studies are still being run, especially in light of the Omicron surge and the virus’ ability to evolve.
If you are not happy with the results below please do another search
50 search results for:
President Joe Biden said on Thursday 14.5 million Americans have signed up for health insurance since Nov. 1, attributing the progress to the passage of his pandemic relief package and the re-opening of an online health insurance marketplace last year.
Researchers studying Merck & Co. Inc.’s cancer drug Keytruda for HIV patients who also have cancer say the immunotherapy may help displace the virus from human immune cells, offering an intriguing area of study for treatment of chronic HIV infection.
U.S. cities and counties have embraced a proposed settlement worth up to $26 billion resolving lawsuits alleging three large drug distributors and drugmaker Johnson & Johnson fueled the U.S. opioid epidemic, lawyers behind the deal said on January 26, increasing the odds that it will move forward.
Moderna Inc. started a mid-stage study, testing a booster dose of the company’s COVID-19 vaccine specifically designed to target the Omicron coronavirus variant, a day after rival Pfizer Inc. launched a similar trial.
COVID-19 vaccines using mRNA technology do not affect fertility outcomes during in-vitro fertilization (IVF), researchers found. Other new findings suggest the bacteria living in the small intestine may contribute to the risk for long COVID after infection with SARS-CoV-2.
Abbott Laboratories beat fourth-quarter 2021 profit and sales estimates, aided by robust sales of COVID-19 test kits and strong demand for the company’s diagnostics products, but forecast lower-than-expected COVID-19 testing sales in 2022 due to uncertainties around the future of the pandemic.
BlueWillow Biologics demonstrated the safety and immunogenicity in humans of the company’s intranasal technology, which CEO Chad Costley said is the only adjuvanted intranasal platform that is not virus-based.
Kyverna Therapeutics secured an additional $85 million following a successful Series B financing round to support various projects in the company’s pipeline of therapies for autoimmune and inflammatory diseases.
Marina Maher Communications (MMC) announced the hire of Joshua Wu, PhD., as Senior Vice President, Performance Analytics.